Phase 3 pivotal study of NVD 003
Latest Information Update: 07 Dec 2023
At a glance
- Drugs NVD-003 (Primary)
- Indications Pseudoarthrosis
- Focus Registrational; Therapeutic Use
- 07 Dec 2023 New trial record
- 05 Dec 2023 According to a Novadip Biosciences media release, this trial will support NVD-003's approval by the US Food and Drug Administration (FDA).